Nanjing Legend Biotech Co.
7 clinical trials · Sponsor
◉ Watch Nanjing Legend Biotech Co.
| Record | Firm | Date |
|---|---|---|
| A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) (NCT07331272) | Nanjing Legend Biotech Co. | 2026-01-29 |
| A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases (NCT07095075) | Nanjing Legend Biotech Co. | 2025-10-14 |
| LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma (NCT07100067) | Nanjing Legend Biotech Co. | 2025-09-16 |
| A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases (NCT07049081) | Nanjing Legend Biotech Co. | 2025-07-17 |
| A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases (NCT06866080) | Nanjing Legend Biotech Co. | 2025-06-17 |
| A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma (NCT03758417) | Nanjing Legend Biotech Co. | 2019-01-23 |
Track Nanjing Legend Biotech Co. automatically
Every clearance here is in the API, with alerts when new ones post.